



SDI Review Form 1.6

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	2014_BJMMR_13820
Title of the Manuscript:	Dose-dependent Modulation of Lipid Parameters and Inflammatory Biomarkers by $\delta\textsc{-}Tocotrienol$ in Hypercholesterolemic Subjects
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that \underline{NO} manuscript should be rejected only on the basis of 'lack of Novelty', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

www.sciencedomain.org



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer,
		correct the manuscript and highlight that part in
		the manuscript. It is mandatory that authors
		should write his/her feedback here)
Compulsory REVISION comments		
	1- Abstract: please differentiate between miRNA	
	and mRNA [please mention this difference in	
	mat & methods] micro ribonuclear acids and	
	messenger RNA???????????????	
	The present study is a dose-response study	
	examined the effects of δ-tocotrienol free from	
	tocopherols on serum lipid parameters and	
	several inflammatory biomarkers (TNF-α, IL-4, IL-	
	6, IL-8) including circulating miRNAs expression in	
	hypercholesterolemic subjects for 30-weeks	
	Trypercholesterolernic subjects for 50-weeks	
	However, the conclusion The present results	
	confirm that consumption of δ-tocotrienol plus	
	AHA Step-1 diet causes significant therapeutic	
	effects → Title include only δ-tocotrienol→ the	
	authors should change the title to " a	
	combination bet. δ-tocotrienol and AHA step 1	
	diet" to be more representable to the results of	
	the study.	
	2- Introduction is good with a clear research	
	question at its end	
	3- At line 113: give a title of a paragraph	
	materials: as the authors mentioned some of	
	their materials and their source. Then at the	
	same paragraph, they should mention the	

www.sciencedomain.org



SDI Review Form 1.6

commercial kits [name, company, country] of all the measured parameters in the study.

<u>Line 114: please mention your reference of serum</u> total cholesterol level > 5.50 mmol/L that means = a hypercholest. Patient.

Mention type of consent: oral or written

At line 124: they mentioned exclusion criteria with no obvious inclusion criteria. I preferred under study design to place 2 titles: inclusion criteria (1,2,3....) then exclusion criteria (1,2,3,....) then causes of termination of study: death- severe illness- hospitalization etc... I think that these 3 subtitles are very important for any clinical trial.

Sample size: please justify the number of 30 patientsyour randomization method- the computer program used, if any, its version, company and country

In figure 2, in title of the study, in methodology: the authors must place AHA step 1 diet + <u>\delta\text{-tocotrienol}</u> to avoid any confusion [I went up and down to understand the presence of this combination]

Results are well explained and self explanatory.

<u>Discussion is good and explains results in</u> relation to other studies in a good manner

Up-to-date and relevant references

www.sciencedomain.org



SDI Review Form 1.6

Minor REVISION comments		
Optional/General comments	. A good research question with a well-done laboratory work. But we need justification of sample size and the method of randomization	

Reviewer Details:

Name:	Sahar Mohamed Kamal Shams El-Dine
Department, University & Country	Pharmacology Department, Ain Shams University, Egypt

Created by: EA Checked by: ME Approved by: CEO Version: 1.6 (07-06-2013)